AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38288922 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab responders (those who reached MDA at 16 weeks)
Number of subjects: 245
Study 38288922 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate responders (those who reached MDA at 16 weeks)
Number of subjects: 245
Study 38288922 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab non-responders (those who did not reach MDA at 16 weeks)
Number of subjects: 245
Study 38288922 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate non-responders (those who did not reach MDA at 16 weeks)
Number of subjects: 245
Study 38288923 — intervention group
Group type: EXPERIMENTAL
Intervention: Anifrolumab 300 mg intravenously once every 4 weeks for 48 weeks
Number of subjects: 726
Study 38288923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 726
Study 38288936 — intervention group
Group type: EXPERIMENTAL
Intervention: Anifrolumab 300 mg
Number of subjects: 726
Study 38288936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 726
Study 38288937 — intervention group
Group type: EXPERIMENTAL
Intervention: secukinumab 300 mg
Number of subjects: 0
Study 38288937 — intervention group
Group type: EXPERIMENTAL
Intervention: secukinumab 150 mg
Number of subjects: 0
Study 38288937 — intervention group
Group type: EXPERIMENTAL
Intervention: secukinumab 150 mg no loading dose (NL)
Number of subjects: 0
Study 38288937 — intervention group
Group type: EXPERIMENTAL
Intervention: secukinumab 150 mg NL
Number of subjects: 0
Study 38288937 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 38288945 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuffless blood pressure monitoring device (Somnotouch-NIBP)
Number of subjects: 166
Study 38288945 — intervention group
Group type: COMPARATOR
Intervention: Cuff-based blood pressure monitoring device (Spacelabs 90217A/IEM Mobil-O-graph)
Number of subjects: 166
Study 38289301 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillatory PEP-therapy using Acapella DHGreen device, 10-12 hours after tracheal extubation, 3 times a day for 3 days after surgery.
Number of subjects: 60
Study 38289301 — intervention group
Group type: COMPARATOR
Intervention: Control group (no respiratory therapy).
Number of subjects: 60
Study 38289301 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillatory PEP-therapy.
Number of subjects: 60
Study 38289602 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Critical Care Recovery Program (m-CCRP) - a 12-month nurse-led collaborative care intervention supported by an interdisciplinary team.
Number of subjects: 466
Study 38289602 — intervention group
Group type: COMPARATOR
Intervention: Control group - telephone-based intervention.
Number of subjects: 466
Study 38289603 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Sleeve Gastrectomy (SG)
Number of subjects: 1735
Study 38289603 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic Roux-en-Y Gastric Bypass (RYGB)
Number of subjects: 1735
Study 38289604 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance Care Planning (ACP) intervention conducted by health care workers; 45- to 60-minute discussions, conducted remotely after March 13, 2020.
Number of subjects: 426
Study 38289604 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance Care Planning (ACP) intervention
Number of subjects: 426
Study 38289604 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 426
Study 38289663 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week self-guided mindfulness-based stress reduction workbook program (e-book or paper option)
Number of subjects: 25
Study 38289663 — intervention group
Group type: COMPARATOR
Intervention: 10-week wait (control group)
Number of subjects: 25
Study 38289666 — intervention group
Group type: EXPERIMENTAL
Intervention: VR therapy (360° VR films on a head-mounted display for up to 20 minutes every 1 to 3 days)
Number of subjects: 69
Study 38289666 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 69
Study 38289673 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation Training (PMRT) with Personalized Virtual Reality (VR) exposure
Number of subjects: 72
Study 38289673 — intervention group
Group type: COMPARATOR
Intervention: Progressive Muscle Relaxation Training (PMRT) with Guided Imagery (GI) exposure
Number of subjects: 72
Study 38289823 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered Toothbrush (PTB)
Number of subjects: 328
Study 38289823 — intervention group
Group type: COMPARATOR
Intervention: Manual Toothbrush (MTB)
Number of subjects: 328
Study 38289907 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Omicron and Delta variants
Number of subjects: 0
Study 38289999 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineralocorticoid receptor antagonist
Number of subjects: 0
Study 38290108 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax 400 mg daily after initial ramp-up until progressive disease
Number of subjects: 158
Study 38290135 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on parsaclisib 10 or 20 mg, once daily for 8 weeks, then once weekly thereafter (daily-to-weekly dosing)
Number of subjects: 74
Study 38290135 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on parsaclisib 5 or 20 mg, once daily for 8 weeks, then 5 mg once daily thereafter (all-daily dosing)
Number of subjects: 74
Study 38290135 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on parsaclisib (daily-to-weekly dosing)
Number of subjects: 74
Study 38290135 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on parsaclisib (all-daily dosing)
Number of subjects: 74
Study 38290135 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on parsaclisib
Number of subjects: 74
Study 38290574 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized nutritional support
Number of subjects: 2028
Study 38290574 — intervention group
Group type: COMPARATOR
Intervention: Usual care nutrition
Number of subjects: 2028
Study 38290574 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted NRS
Number of subjects: 2028
Study 38290574 — intervention group
Group type: EXPERIMENTAL
Intervention: Original NRS and MNA
Number of subjects: 2028
Study 38290574 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted MNA
Number of subjects: 2028
Study 38290699 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamon (4 g/d)
Number of subjects: 18
Study 38290699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 38290741 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold application (cold gel packs applied 12 times for 15 min at 2-h intervals)
Number of subjects: 79
Study 38290741 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients receiving amiodarone treatment without cold application)
Number of subjects: 79
Study 38290741 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold application
Number of subjects: 79
Study 38290741 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 79
Study 38290758 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-assisted colonoscopy (AI-C)
Number of subjects: 240
Study 38290758 — intervention group
Group type: COMPARATOR
Intervention: Conventional colonoscopy (CC)
Number of subjects: 240
Study 38290769 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligo-fractionated irradiation (22.5 Gy/5 fractions/5 days) followed by nivolumab every 2 weeks
Number of subjects: 20
Study 38290996 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary periodontal-orthodontic treatment (mucogingival surgery using subepithelial connective tissue graft followed by orthodontic treatment)
Number of subjects: 36
Study 38290996 — intervention group
Group type: COMPARATOR
Intervention: Mucogingival surgery alone (control group)
Number of subjects: 36
Study 38290996 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary periodontal-orthodontic treatment
Number of subjects: 36
Study 38291017 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroendoscopic hematoma evacuation surgery
Number of subjects: 560
Study 38291017 — intervention group
Group type: COMPARATOR
Intervention: Standard conservative treatment
Number of subjects: 560
Study 38291174 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia with programmed intermittent bolus plus patient-controlled epidural analgesia regimen
Number of subjects: 30
Study 38291214 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive social support
Number of subjects: 0
Study 38291214 — intervention group
Group type: EXPERIMENTAL
Intervention: Detrimental interactions
Number of subjects: 0
Study 38291279 — intervention group
Group type: EXPERIMENTAL
Intervention: Bamlanivimab (BAM) 175 mg + Etesevimab (ETE) 350 mg
Number of subjects: 927
Study 38291279 — intervention group
Group type: EXPERIMENTAL
Intervention: Bamlanivimab (BAM) 700 mg + Etesevimab (ETE) 1400 mg
Number of subjects: 927
Study 38291279 — intervention group
Group type: EXPERIMENTAL
Intervention: Bamlanivimab (BAM) 2800 mg + Etesevimab (ETE) 2800 mg
Number of subjects: 927
Study 38291279 — intervention group
Group type: EXPERIMENTAL
Intervention: Bamlanivimab (BAM) 700 mg alone
Number of subjects: 927
Study 38291279 — intervention group
Group type: EXPERIMENTAL
Intervention: Bamlanivimab (BAM) 350 mg + Etesevimab (ETE) 700 mg
Number of subjects: 927
Study 38291279 — intervention group
Group type: EXPERIMENTAL
Intervention: Bamlanivimab (BAM) 700 mg + Sotrovimab 500 mg
Number of subjects: 927
Study 38291279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 927
Study 38291280 — intervention group
Group type: EXPERIMENTAL
Intervention: Kukoamine B mesylate (KB) at doses of 0.005 mg/kg, 0.02 mg/kg, 0.04 mg/kg, 0.08 mg/kg, 0.12 mg/kg, 0.24 mg/kg, 0.48 mg/kg
Number of subjects: 52
Study 38291280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 38291301 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Number of subjects: 20
Study 38291301 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegan diet
Number of subjects: 20
Study 38291369 — intervention group
Group type: EXPERIMENTAL
Intervention: Woebot for Mood & Anxiety (W-MA-02)
Number of subjects: 256
Study 38291372 — intervention group
Group type: EXPERIMENTAL
Intervention: Tovorafenib, administered once weekly at 420 mg/m2
Number of subjects: 0
Study 38291372 — intervention group
Group type: COMPARATOR
Intervention: Current standard of care (SoC) chemotherapy
Number of subjects: 0
Study 38291408 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomous motivation
Number of subjects: 58
Study 38291408 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled motivation
Number of subjects: 58
Study 38291650 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ocular surface workup using Oculus Keratograph (K5 M)
Number of subjects: 120
Study 38291865 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib (12 mg for bodyweight ≥60 kg, 8 mg for bodyweight <60 kg) orally once daily, sintilimab (200 mg) intravenously once every 3 weeks, and on demand TACE
Number of subjects: 30
Study 38291897 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 million IU cholecalciferol oral
Number of subjects: 90
Study 38291897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 38291916 — intervention group
Group type: EXPERIMENTAL
Intervention: Favorite music
Number of subjects: 0
Study 38291916 — intervention group
Group type: COMPARATOR
Intervention: White noise
Number of subjects: 0
Study 38292039 — intervention group
Group type: EXPERIMENTAL
Intervention: M-M-RVaxPro
Number of subjects: 6540
Study 38292039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6540
Study 38292041 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradient Boosting Classifier (GBC) model
Number of subjects: 689
Study 38292042 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegzilarginase
Number of subjects: 32
Study 38292042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 38292279 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocolized sedation and analgesia
Number of subjects: 69
Study 38292279 — intervention group
Group type: COMPARATOR
Intervention: Control group (without protocol)
Number of subjects: 69
Study 38292350 — intervention group
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Number of subjects: 165
Study 38292350 — intervention group
Group type: EXPERIMENTAL
Intervention: remdesivir
Number of subjects: 165
Study 38292350 — intervention group
Group type: COMPARATOR
Intervention: standard of care
Number of subjects: 165
Study 38292350 — intervention group
Group type: EXPERIMENTAL
Intervention: TFPI
Number of subjects: 165
Study 38292386 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Hub intervention group (LH)
Number of subjects: 106
Study 38292386 — intervention group
Group type: COMPARATOR
Intervention: WL group (control)
Number of subjects: 106
Study 38292889 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric marking pen (Comfort Marker 2.0, CM)
Number of subjects: 92
Study 38292889 — intervention group
Group type: COMPARATOR
Intervention: Lancets
Number of subjects: 92
Study 38293149 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-quantity lipid-based nutrient supplements (SQ-LNS)
Number of subjects: 0
Study 38293149 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother-infant fucosyltransferase status and infant gut microbiome
Number of subjects: 0
Study 38293200 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed low-dose-rate radiation (PLDR) combined with chemotherapy
Number of subjects: 0
Study 38293200 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemoradiation
Number of subjects: 0
Study 38293643 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragmatic ultrasound assessment within the first 24 hours of admission
Number of subjects: 68
Study 38293926 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD), N=556
Number of subjects: 1116
Study 38293926 — intervention group
Group type: COMPARATOR
Intervention: Usual care, N=550
Number of subjects: 1116
Study 38293957 — intervention group
Group type: EXPERIMENTAL
Intervention: ABBV-599 (upadacitinib 15 mg plus elsubrutinib 60 mg)
Number of subjects: 242
Study 38293957 — intervention group
Group type: EXPERIMENTAL
Intervention: upadacitinib 15 mg
Number of subjects: 242
Study 38293957 — intervention group
Group type: EXPERIMENTAL
Intervention: elsubrutinib 60 mg
Number of subjects: 242
Study 38293957 — intervention group
Group type: EXPERIMENTAL
Intervention: elsubrutinib 20 mg
Number of subjects: 242
Study 38293957 — intervention group
Group type: EXPERIMENTAL
Intervention: elsubrutinib 5 mg
Number of subjects: 242
Study 38293957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study 38294008 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m2)
Number of subjects: 56
Study 38294008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 38294016 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (50 Allergan units) in 1 mL of saline
Number of subjects: 60
Study 38294016 — intervention group
Group type: COMPARATOR
Intervention: Saline injection (1 mL)
Number of subjects: 60
Study 38294032 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported self-management group (n=40)
Number of subjects: 60
Study 38294032 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (n=20)
Number of subjects: 60
Study 38294084 — intervention group
Group type: EXPERIMENTAL
Intervention: PLX-PAD
Number of subjects: 213
Study 38294084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study 38294084 — intervention group
Group type: EXPERIMENTAL
Intervention: PLX-PAD (subpopulation with HbA1c < 6.5%)
Number of subjects: 213
Study 38294084 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subpopulation with HbA1c < 6.5%)
Number of subjects: 213
Study 38294091 — intervention group
Group type: EXPERIMENTAL
Intervention: LY3509754 (10-2000 mg single ascending dose or 100-1000 mg multiple ascending dose for 14 days)
Number of subjects: 91
Study 38294091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 38294158 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenapanor (50 mg twice a day)
Number of subjects: 1372
Study 38294158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1372
Study 38294158 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly CSBM status
Number of subjects: 1372
Study 38294498 — intervention group
Group type: EXPERIMENTAL
Intervention: LAAO
Number of subjects: 638
Study 38294575 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental or standard-of-care Enzyme Replacement Therapy (ERT)
Number of subjects: 123
Study 38294813 — intervention group
Group type: EXPERIMENTAL
Intervention: Sudarshan Kriya Yoga (SKY)
Number of subjects: 129
Study 38294813 — intervention group
Group type: COMPARATOR
Intervention: Stress Management Education (SME)
Number of subjects: 129
Study 38294848 — intervention group
Group type: EXPERIMENTAL
Intervention: Chance2Act intervention
Number of subjects: 124
Study 38294848 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 124
Study 38294865 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine plus standard care
Number of subjects: 0
Study 38294865 — intervention group
Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 0
Study 38294866 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based Building Resilience At Work (BRAW) program
Number of subjects: 33
Study 38294895 — intervention group
Group type: EXPERIMENTAL
Intervention: CUSA Clarity Ultrasonic Surgical Aspirator System
Number of subjects: 0
Study 38294895 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38294975 — intervention group
Group type: EXPERIMENTAL
Intervention: NTLA-2002 25 mg
Number of subjects: 10
Study 38294975 — intervention group
Group type: EXPERIMENTAL
Intervention: NTLA-2002 50 mg
Number of subjects: 10
Study 38294975 — intervention group
Group type: EXPERIMENTAL
Intervention: NTLA-2002 75 mg
Number of subjects: 10
Study 38294975 — intervention group
Group type: EXPERIMENTAL
Intervention: NTLA-2002 (all doses)
Number of subjects: 10
Study 38294972 — intervention group
Group type: EXPERIMENTAL
Intervention: Butantan-DV
Number of subjects: 16235
Study 38294972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16235
Study 38294974 — intervention group
Group type: EXPERIMENTAL
Intervention: NALL for 12 weeks
Number of subjects: 60
Study 38294974 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 60
Study 38294974 — intervention group
Group type: COMPARATOR
Intervention: NALL vs Placebo
Number of subjects: 60
Study 38294974 — intervention group
Group type: COMPARATOR
Intervention: NALL and Placebo
Number of subjects: 60
Study 38294973 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.7% iodine povacrylex in 74% isopropyl alcohol (iodine group)
Number of subjects: 8485
Study 38294973 — intervention group
Group type: COMPARATOR
Intervention: 2% chlorhexidine gluconate in 70% isopropyl alcohol (chlorhexidine group)
Number of subjects: 8485
Study 38294973 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 8485
Study 38295049 — intervention group
Group type: EXPERIMENTAL
Intervention: Camera Heart Rate Variability (CHRV) app for resonance frequency breathing training.
Number of subjects: 60
Study 38295131 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 57
Study 38295131 — intervention group
Group type: COMPARATOR
Intervention: Palpation
Number of subjects: 57
Study 38295144 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel and Carboplatin with Low-intensity Pulsed Ultrasound and Microbubbles (LIPU/MB)
Number of subjects: 0
Study 38295144 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (monotherapy)
Number of subjects: 0
Study 38295144 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin (monotherapy)
Number of subjects: 0
Study 38295280 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooccurring favorable-risk mutations (NPM1, CEBPA, t(8;21), or inv(16))
Number of subjects: 464
Study 38295280 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooccurring poor-risk mutations (WT1, UBTF, or NUP98::NSD1)
Number of subjects: 464
Study 38295280 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate risk (lacking either favorable-risk or poor-risk mutations)
Number of subjects: 464
Study 38295280 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified therapy (consolidation transplant in remission)
Number of subjects: 464
Study 38295280 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified therapy including sorafenib for ITDpos/NUP98::NSD1
Number of subjects: 464
Study 38295317 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy + Bevacizumab (CT + B)
Number of subjects: 239
Study 38295317 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only (CT)
Number of subjects: 239
Study 38295339 — intervention group
Group type: EXPERIMENTAL
Intervention: DaxibotulinumtoxinA 125U
Number of subjects: 301
Study 38295339 — intervention group
Group type: EXPERIMENTAL
Intervention: DaxibotulinumtoxinA 250U
Number of subjects: 301
Study 38295339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 38295507 — intervention group
Group type: EXPERIMENTAL
Intervention: Cottonseed oil (CSO)
Number of subjects: 42
Study 38295507 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (OO)
Number of subjects: 42
Study 38295773 — intervention group
Group type: EXPERIMENTAL
Intervention: Education at the community and individual level; Intensive health wellness coaching
Number of subjects: 0
Study 38295773 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel stroke biomarkers
Number of subjects: 0
Study 38295948 — intervention group
Group type: EXPERIMENTAL
Intervention: T-piece
Number of subjects: 25
Study 38295948 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-support ventilation (PSV)
Number of subjects: 25
Study 38295949 — intervention group
Group type: EXPERIMENTAL
Intervention: High PEEP
Number of subjects: 16
Study 38295949 — intervention group
Group type: COMPARATOR
Intervention: Low PEEP
Number of subjects: 16
Study 38295954 — intervention group
Group type: EXPERIMENTAL
Intervention: Ficonalkib (SY-3505) at 800 mg QD in phase 1
Number of subjects: 127
Study 38295954 — intervention group
Group type: EXPERIMENTAL
Intervention: Ficonalkib (SY-3505) at 600 mg QD in phase 2
Number of subjects: 127